Depomed announced that it has made available the once-daily formulation of Gralise (gabapentin tablets) for the treatment of postherpetic neuralgia (PHN). Gralise utilizes a proprietary patented polymer technology to gradually release the drug and is not interchangeable with other gabapentin products because of differing pharmacokinetic profiles that affect the frequency of administration.

Gralise is available in 300mg and 600mg dosage strength tablets.

For more information call (866) 458-6389 or visit